ClinicalTrials.gg
TerminatedNCT00330135Updated Jan 9, 2008

The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis

A Phase 3 interventional study of Sodium hyaluronate and placebo injection in Symptomatic Hip Osteoarthritis, sponsored by Daiichi Sankyo. Terminated at 1 site in France. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-01-09.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.

Enrollment
13th of 20
85 · median 130
Started
2005
with 1 other
Phase 3
6 of 38
none open now
Registered
2nd of 38
by date

Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2005, is one of 6 in phase 3, and was the 2nd registered.

Osteoarthritis, Hip

641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 87 Osteoarthritis, Hip studies recruiting now, 54 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Osteoarthritis, Hip with a site in France, or all of them as a file.
02

Study summary

To demonstrate the difference in terms of symptomatic efficacy between ADANT® sodium hyaluronate and placebo following an intra-articular injection in patients with symptomatic osteoarthritis of the hip.

Each patient will receive an injection of sodium hyaluronate or placebo in the symptomatic hip and will be followed up for three months.

At the third month, if the score for overall pain is still > 40 mm on the VAS, a second injection of ADANT® can be given irrespective of which treatment was received previously. The patient will be followed up for a further 3 months in an open-label fashion (monthly visits).

03

Conditions studied

  • Symptomatic Hip Osteoarthritis

Browse trials for

Keywords

  • hip osteoarthritis
  • Hyaluronic acid
  • Viscosupplementation
  • intra-articular injections
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Primary osteoarthritis of the hip defined according to the ACR criteria; symptomatic, 2. Osteoarthritis of radiological grade II to III according to the Kellgren-Lawrence classification, using X-rays performed during the last three months, 3. Overall pain intensity between 40 and 80 mm on a VAS of 100 mm at the pre-screening examination, 4. The patients experienced pain at least one in two days during the last 30 days, it was resistant to paracetamol treatment at a dose of 4 g/day and a step 2 analgesic or a NSAID taken for at least 10 days, 5. A prosthesis is not planned in the next six months.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding or women who could become pregnant and are not using effective ,
  • Major dysplasia (defined using Lequesne's criteria as dislocation of the hip),
  • Treatment by intra-articular injection of hyaluronic acid in the symptomatic hip during the 6 months prior to pre-screening,
  • Patients with a history of to any of the ingredients in the hyaluronan,
  • The presence of inflammatory arthropathy or another disorder or condition that could affect the joint (e.g., rheumatoid arthritis, metabolic bone disease, femoral head necrosis, psoriasis, gout, infection),
  • Another muscular or skeletal condition that could interfere with the evaluation of the efficacy of the treatment on the hip in question (evaluation of pain or functional handicap),
  • Systemic therapy or intra-articular injection of corticosteroids into the ipsilateral hip or knee within the last month,
  • Intermittent claudication or vascular disease,
  • Previous surgery on the hip in question,
  • Septic arthritis at any site,
  • Any surgical procedure, including arthroplasty or arthroscopy, to the hip during the six months prior to pre-screening or surgery scheduled during the trial,
  • Any chronic skin condition that could affect the site of the injection,
  • Use of the treatment or material during the last three months,
  • Oral or injectable anticoagulant treatment,
  • Antiaggregant treatment, particularly low-dose aspirin,
  • Symptomatic chondrocalcinosis in the painful hip
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    1

    Sodium hyaluronate 2.5 ml - 1 injection

    Drug: Sodium hyaluronate

  • Placebo comparator
    2

    Placebo injection - 1 injection

    Drug: placebo injection

Interventions

  • Sodium hyaluronate 2.5 ml - 1 injection

  • Drugplacebo injection

    placebo injection - 1 injection

06

What researchers measure

Primary outcomes

  1. Change in overall pain, 3 months after a single intra-articular injection. The intensity of the pain will be evaluated using a continuous VAS of 100 mm of the overall level of pain in the affected hip.

    Time frame: 3 months

Secondary outcomes

  1. Proportion of responding patients and proportion of patients with a symptomatic response (OARSI criterion)

    Time frame: 3 months

  2. WOMAC index (the 3 subscales)

    Time frame: 3 months

  3. Consumption of analgesics and NSAIDs

    Time frame: 3 months

  4. Evaluation of tolerability (AE reporting)

    Time frame: 3 months

07

Study locations

1 site
  • Rueil-Malmaison, France
08

References and documents

Publications

  • Richette P, Ravaud P, Conrozier T, Euller-Ziegler L, Mazieres B, Maugars Y, Mulleman D, Clerson P, Chevalier X. Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. Arthritis Rheum. 2009 Mar;60(3):824-30. doi: 10.1002/art.24301. PubMed 19248105 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2006
First posted
May 25, 2006
Start
Jan 2005
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Jan 9, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00330135
Lead sponsor
Daiichi Sankyo
First posted
May 25, 2006
Start date
Jan 2005
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Jan 9, 2008

Study contacts

Xavier Chevalier, Professor
principal investigator · Head of the department of rheumatology Hopital Henri Mondor, Creteil, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion